Shirley D’Sa: What Comes After BTK Inhibitors in Waldenström Macroglobulinaemia?
Shirley D’Sa, Professor of Haematology at United KingdomUnited Kingdom, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Hematology Reports, adding:
”Treatment options following BTK inhibitor failure in Waldenström macroglobulinaemia (WM) remain an important unmet need in our field.
Our recently published article explores the role of bortezomib-based therapy in patients who have progressed following BTKi treatment, providing valuable real-world evidence in an area where prospective data remain limited.
As the therapeutic landscape of WM continues to evolve—with non-covalent BTK inhibitors, BTK degraders, BCL2 inhibitors, bispecific antibodies and cellular therapies all under investigation—it is important not to overlook the potential utility of established agents such as proteasome inhibitors.
The paper contributes to the growing discussion around treatment sequencing in WM and the question many of us increasingly face in clinical practice: what comes after BTKi?
An interesting read for anyone involved in the care of patients with WM and related IgM disorders.”
Title: Bortezomib in Patients Who Fail BTKi in Waldenström Macroglobulinaemia
Authors: Tahanzaib Khwaja, Nicole Japzon, Simona Gatto, Jindriska Lindsay, Charalampia Kyriakou, Shirley D’Sa

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 13, 2026, 13:2810 Posts Not To Miss from ISTH 2026, Part 2
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!